Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is≠ market-oriented and realizes industrial development through R&D innovation and tech∑nology transformation.

key word:

Pharmaceutical innovative

Category:

Consulting
Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry f♦inance platform company integrating pharmaceutical, intelligent medical, bio pharλmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault "reaction, nitration reaction, sulfonation reaction, hydrogenation reaction, fluorination reaεction, chlorination reaction, bromination reaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. ≈In October 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 inhibitor for <the treatment of type ⅱ diabetes mellitus. The characteristics of this drug ar€e that it can stimulate insulin secretion while reduci®ng hunger without causing weight gain. Hypoglycemia and ed♦ema will not occur, and it is suitable for diabetic patients with poor blood glucose co‍ntrol and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise≤ that is market-oriented and realizes industrial development through R&D innovation and t±echnology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most import₩ant products for the treatment of arthritis. It is well tolerated and has a low incidence of sidπe effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonΩists. In clinical application, it has good therapeutic effect on atopic asthma and othπer types of bronchial asthma, and the market prospect is huge. In the major cat™egory of asthma drugs, leukotriene receptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that 'is market-oriented and realizes industrial development through R&D innovation and technology∞ transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved εby FDA for Alzheimer's disease in the United States. Its treat€ment reaches the target dose and has low toxic and side >effects. It has been widely recognized by our medical community, and good t¥olerance is its biggest advantage. In October 1999, Donepezil wa s launched in China under the trade name "Aricept", which ∞is the main chemical drug against Alzheimer's disease. At present, C‍FDA has approved a number of domestic enterprises to produce donepezil preparations, the main dos←age forms are tablets, capsules, dispersive tablets, oδral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eli♣quis, Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved f≤or use in the 27 EU member states. The world's first drug approved to prevent• venous thromboembolism (VTE) in adult patients un≠dergoing elective hip or knee replacement. From June 2019 to June 2020, the annual ​sales of apixaban products overseas reached about $15.4 billion, with a year-on-year growth of nαearly 32%, and the API consumption reached about 23,960 kg, with a year-on-year growth ofε about 28%. Compared with its main competitor, Rivaroxaba←n, the drug's annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutic¥al enterprise that is market-oriented and realizes industrial development thr÷ough R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On Dec↑ember 29, 2004, it was approved by FDA for the treatment of refractory or relapsed acute lym'phoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech p harmaceutical enterprise that is market-oriented and re¥alizes industrial development through R&D innovation and technology transfo‍rmation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need oth¥er services, E-mail: 2880705932@qq.com
Submit